Back to results
US 2022/0031665 A1Published application
Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) nano-formulation of compounds and methods of using the same
AssigneeShifa Biomedical Corporation
InventorsShaker A. Mousa, Nabil A. Elshourbagy, Harold V. Meyers, Sherin Salaheldin Abdel-Meguid
Life of this patent
Estimating the term…
Abstract
Disclosed are Nanoformulated compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL- and related cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
Claims41
1:
- A nanoparticle comprising at least one PCSK9 antagonist encapsulated within the nanoparticle, wherein said PCSK9 antagonist is a compound of Formula (I):
- including pharmaceutically acceptable salts and stereoisomers of said compound,
- wherein R1 is H or CH3;
- R2 and R3 are independently selected from the group consisting of H, halogen, (C1-C3)-alkyl and (C1-C3)-alkoxy;
- and R4 is selected from the group consisting of CO2R5, CONR5R6, aryl, and heteroaryl, wherein R5 and R6 are independently selected from the group consisting of H and (C1-C3)-alkyl.
2 more elements
2:
- The nanoparticle of claim 1, wherein R4 is an aryl or heteroaryl.
3:
- The nanoparticle of claim 2, wherein R4 is selected from the group consisting of 2-oxazole, 2-oxazoline, 2-benzoxazole and 2-benzimidazole.
4:
- The nanoparticle of claim 1, wherein said PCSK9 antagonist is a compound of Formula (II):
- including pharmaceutically acceptable salts and stereoisomers of said compounds,
- wherein R1 is H or CH3;
- R2 is H or methoxy;
- R3 is H or halogen;
- and R7 is independently selected from the group consisting of H and (C1-C2)-alkyl or R7 are taken together to form an optionally substituted 6-membered carbocycle.
3 more elements
5:
- The nanoparticle of claim 4, wherein if R1 is H, then R2 is H, and if R1 is methyl then R2 is methoxy.
6:
- The nanoparticle of claim 4, wherein R7 are taken together to form an aryl.
7:
- The nanoparticle of claim 1, wherein said halogen is fluorine.
8:
- The nanoparticle of claim 1, wherein said PCSK9 antagonist is selected from the group consisting of SBC-115,418, SBC-115,433, SBC-115,448, SBC-115,462 and SBC-115,477.
9:
- The nanoparticle of claim 1, wherein said PCSK9 antagonist is SBC-115,418.
10:
- The nanoparticle of claim 1, wherein said nanoparticles are hydrophobic.
11:
- The nanoparticle of claim 1, wherein said nanoparticles are chitosan hybrid nanoparticles, amine-modified poly-(lactic-co-glycolic acid) (PLGA) nanoparticles, solid lipid nanoparticles (SLNs), polyvinyl pyrrolidone (PVP) nanoparticles, hydroxypropyl methylcellulose acetate succinate (HPMC-AS) nanoparticles, or combinations thereof.
12:
- The nanoparticle of claim 11, wherein said nanoparticles comprise chitosan and poly-(lactic-co-glycolic acid) (PLGA).
13:
- The nanoparticle of claim 11, wherein said nanoparticles comprise polyvinyl pyrrolidone (PVP) and hydroxypropyl methylcellulose acetate succinate (HPMC-AS).
14:
- The nanoparticle of claim 11, wherein said nanoparticles comprise polyvinyl pyrrolidone (PVP) and chitosan.
15:
- The nanoparticle of claim 1, wherein said nanoparticle comprises a liver targeting moiety on the exterior of the nanoparticle.
16:
- The nanoparticle of claim 15, wherein said liver targeting moiety is selected from the group consisting of Glycyrrhetinic acid (GA), Lactobionic acid (LA), Alginic acid and combinations thereof.
17:
- The nanoparticle of claim 11, wherein said chitosan hybrid nanoparticle is selected from the group consisting of chitosan cross-linked to fatty acids, chitosan cross-linked to amino acids, chitosan cross-linked to hyaluronic acid, chitosan cross-linked to deoxycholic acid, chitosan cross-linked to Alginic acid, chitosan cross-linked to PLGA, and chitosan cross-linked to collagen-hydroxyapatite.
18:
- The nanoparticle of claim 17, wherein said fatty acids are selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), DHA and EPA, linoleic acid, and combinations thereof.
19:
- The nanoparticle of claim 17, wherein said amino acids comprise arginine.
20:
- The nanoparticle of claim 1, wherein said nanoparticle further encapsulates at least one other LDL-lowering substance.
21:
- The nanoparticle of claim 20, wherein said LDL-lowering substance is an anti-dyslipidemia agent.
22:
- The nanoparticle of claim 21, wherein said anti-dyslipidemia agent is a statin, ezetimibe, bempedoic acid, a thyroid hormone receptor beta agonist, or a combination thereof.
23:
- A composition comprising a nanoparticle of claim 1 and a physiologically compatible carrier medium.
24:
- A method for delivering a PCSK9 antagonist to the liver of a subject, said method comprising administering at least one nanoparticle claim 1 to said subject.
25:
- The method of claim 24, wherein said subject is human.
26:
- The methods of claim 24, wherein said nanoparticle is administered to said subject in a composition further comprising a physiologically compatible carrier medium.
27:
- A method for lowering serum cholesterol, LDL-C, and/or triglycerides and/or regulating other lipids biomarkers such as free cholesterol, cholesterol ester, HDL-C in a subject, said method comprising administering at least one nanoparticle of claim 1 to said subject.
28:
- The method of claim 27, wherein said subject is human.
29:
- The methods of claim 27, wherein said nanoparticle is administered to said subject in a composition further comprising a physiologically compatible carrier medium.
30:
- The method of claim 27, wherein said subject has a disorder selected from the group consisting of dyslipidemia, atherosclerosis, cardiovascular disease, hypercholesterolemia, familial hypercholesterolemia, obesity, metabolic syndrome, type 2 diabetes, abdominal aortic aneurysms and combinations thereof.
31:
- The method of claim 27, wherein the lowering of serum cholesterol, triglycerides, and/or lipid profile in the subject is sufficient to reduce the subject's cardiovascular risk.
32:
- A method for treating or preventing hypercholesterolemia, and/or at least one symptom of dyslipidemia, atherosclerosis, CVD or coronary heart disease in a patient in need of said treatment, the method comprising administering to said patient a therapeutically effective amount of at least one nanoparticle of claim 1.
33:
- The methods of claim 32, wherein said nanoparticle is administered to said subject in a composition further comprising a physiologically compatible carrier medium.
34:
- The method of claim 24, further comprising the administration of at least one other LDL-lowering substance.
35:
- The method of claim 34, wherein said LDL-lowering substance is an anti-dyslipidemia agent.
36:
- The method of claim 35, wherein said anti-dyslipidemia agent is a statin, ezetimibe, bempedoic acid, a thyroid hormone receptor beta agonist, or a combination thereof.
37:
- Nanoformulation comprising a combination of PVP/HPMC-AS/SBC-115,418 or analogues thereof and a liver targeting moiety.
38:
- The nanoformulation of claim 37 wherein said liver targeting moiety is selected from the group consisting of Glycyrrhetinic acid (GA), Lactobionic acid (LA), Alginic acid or combinations thereof.
39:
- A compound selected from the group consisting of SBC-115,433, SBC-115,448, SBC-115,462 and SBC-115,477.
40:
- The compound of claim 39 selected from the group consisting of SBC-115,448, SBC-115,462 and SBC-115,477.
41:
- The compound of claim 39 which is SBC-115,477.